Eating disorders such as anorexia (AN) and bulimia nervosa (BN) are characterized by abnormal eating behavior. The essential aspect of AN is that the individual refuses to maintain a minimal normal body weight. The main features of BN are binge eating and inappropriate compensatory methods to prevent weight gain. The gut-brain-adipose tissue (AT) peptides and neutralizing autoantibodies play an important role in the regulation of eating behavior and growth hormone release. The mechanisms for controlling food intake involve an interplay between gut, brain, and AT. Parasympathetic, sympathetic, and serotoninergic systems are required for communication between brain satiety centre, gut, and AT. These neuronal circuits include neuropeptides ghrelin, neuropeptide Y (NPY), peptide YY (PYY), cholecystokinin (CCK), leptin, putative anorexigen obestatin, monoamines dopamine, norepinephrine (NE), serotonin, and neutralizing autoantibodies. This extensive and detailed report reviews data that demonstrate that hunger-satiety signals play an important role in the pathogenesis of eating disorders. Neuroendocrine dysregulations of the AT-gut-brain axis peptides and neutralizing autoantibodies may result in AN and BN. The circulating autoantibodies can be purified and used as pharmacological tools in AN and BN. Further research is required to investigate the orexigenic/anorexigenic synthetic analogs and monoclonal antibodies for potential treatment of eating disorders in clinical practice.

Institute of Endocrinology Laboratory of Clinical and Experimental Neuroendocrinology Narodni 8 116 94 Prague 1 Czech Republic

Zobrazit více v PubMed

Hsu LKG. Epidemiology of the eating disorders. Psychiatric Clinics of North America. 1996;19(4):681–700. PubMed

Vitiello B, Lederhendler I. Research on eating disorders: current status and future prospects. Biological Psychiatry. 2000;47(9):777–786. PubMed

Kaye WH, Wagner A, Fudge JL, Paulus M. Neurocircuity of eating disorders. Current Topics in Behavioral Neurosciences. 2011;6:37–57. PubMed PMC

DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC, USA: American Psychiatric Association; 2000.

Meguid MM, Yang Z-J, Gleason JR. The gut-brain brain-gut axis in anorexia: toward an understanding of food intake regulation. Nutrition. 1996;12(1):S57–S62. PubMed

Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. A higher response of plasma neuropeptide Y, growth hormone, leptin levels and extracellular glycerol levels in subcutaneous abdominal adipose tissue to Acipimox during exercise in patients with bulimia nervosa: single-blind, randomized, microdialysis study. Nutrition and Metabolism. 2011;8, article 81 PubMed PMC

Smitka K, Papezova H, Vondra K, Hill M, Hainer V, Nedvidkova J. Short-term exercise combined with Acipimox administration induces an increase in plasma ACTH levels and its subsequent fall in the recovery phase in bulimic women. Regulatory Peptides. 2013;182:45–52. PubMed

Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. Journal of Physiology and Pharmacology. 2004;55(1):137–154. PubMed

Romijn JA, Corssmit EP, Havekes LM, Pijl H. Gut-brain axis. Current Opinion in Clinical Nutrition and Metabolic Care. 2008;11(4):518–521. PubMed

Roth CL, Reinehr T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Archives of Pediatrics and Adolescent Medicine. 2010;164(2):131–138. PubMed

Sedlackova D, Kopeckova J, Papezova H, et al. Changes of plasma obestatin, ghrelin and NPY in anorexia and bulimia nervosa before and after a high-carbohydrate breakfast. Physiological Research. 2011;60:165–173. PubMed

Smitka K, Papezova H, Kvasnickova H, et al. Increased response of growth hormone and ghrelin to exercise and anti-lipolytic drug in bulimia nervosa patients. In: Godoy-Matos A, Wass J, editors. Proceedings of the 13th International Congress of Endocrinology; November 2008; Rio de Janeiro, Brazil. International Proceedings Division, Medimond Srl; pp. 445–449. http://www.medimond.com/proceedings/moreinfo/20081108.htm.

Nedvidkova J, Smitka K, Papezova H, Vondra K, Hill M, Hainer V. Acipimox during exercise points to an inhibitory feedback of GH on ghrelin secretion in bulimic and healthy women. Regulatory Peptides. 2011;167(1):134–139. PubMed

Sedlackova D, Kopeckova J, Papezova H, et al. Comparison of high-carbohydrate and high-protein breakfast effect on plasma ghrelin, obestatin, NPY and PYY levels in women with anorexia and bulimia nervosa. Nutrition & Metabolism. 2012;9:p. 52. PubMed PMC

Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Peccoz P, Peracchi M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. Journal of Clinical Endocrinology and Metabolism. 2003;88(2):701–704. PubMed

Stanley S, Wynne K, McGowan B, Bloom S. Hormonal regulation of food intake. Physiological Reviews. 2005;85(4):1131–1158. PubMed

Zhang JV, Ren P-G, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science. 2005;310(5750):996–999. PubMed

Prince AC, Brooks SJ, Stahl D, Treasure J. Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. American Journal of Clinical Nutrition. 2009;89(3):755–765. PubMed

Kaye WH, Frank GK, Bailer UF, et al. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiology and Behavior. 2005;85(1):73–81. PubMed

Kaye WH, Bailer UF, Frank GK, Wagner A, Henry SE. Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiology and Behavior. 2005;86(1-2):15–17. PubMed

Kontis D, Theochari E. Dopamine in anorexia nervosa: a systematic review. Behavioural Pharmacology. 2012;23:496–515. PubMed

Haleem DJ. Serotonin neurotransmission in anorexia nervosa. Behavioural Pharmacology. 2012;23:478–495. PubMed

Kaye WH, Wierenga CE, Bailer UF, Simmons AN, Bischoff-Grethe A. Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa. Trends in Neurosciences. 2013;36:110–120. PubMed PMC

Nonogaki K, Ohashi-Nozue K, Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochemical and Biophysical Research Communications. 2006;341(3):703–707. PubMed

Bradley RL, Mansfield JPR, Maratos-Flier E. Neuropeptides, including neuropeptide y and melanocortins, mediate lipolysis in murine adipocytes. Obesity Research. 2005;13(4):653–661. PubMed

Schulpis KH, Papassotiriou I, Vounatsou M, Karikas GA, Tsakiris S, Chrousos GP. Morning preprandial plasma ghrelin and catecholamine concentrations in patients with phenylketonuria and normal controls: evidence for catecholamine-mediated ghrelin regulation. Journal of Clinical Endocrinology and Metabolism. 2004;89(8):3983–3987. PubMed

Nedvídková J, Smitka K, Kopský V, Hainer V. Adiponectin, an adipocyte-derived protein. Physiological Research. 2005;54(2):133–140. PubMed

Dostálová I, Smitka K, Papežová H, Kvasničková H, Nedvídková J. The role of adiponectin in increased insulin sensitivity of patients with anorexia nervosa. Vnitrni Lekarstvi. 2006;52(10):887–890. PubMed

Dostálová I, Smitka K, Papežová H, Kvasničková H, Nedvídková J. Increased insulin sensitivity in patients with anorexia nervosa: the role of adipocytokines. Physiological Research. 2007;56(5):587–594. PubMed

Dostalova I, Bartak V, Papezova H, Nedvidkova J. The effect of short-term exercise on plasma leptin levels in patients with anorexia nervosa. Metabolism. 2007;56(4):497–503. PubMed

Vargovic P, Ukropec J, Laukova M, et al. Adipocytes as a new source of catecholamine production. FEBS Letters. 2011;585(14):2279–2284. PubMed

Kvetnansky R, Ukropec J, Laukova M, Manz B, Pacak K, Vargovic P. Stress stimulates production of catecholamines in rat adipocytes. Cellular and Molecular Neurobiology. 2012;32(5):801–813. PubMed PMC

Krykorkova I, Pacak K, Bartak V, Papezova H, Matejkova-Behanova M, Nedvidkova J. Increased basal and maprotiline-stimulated norepinephrine levels in abdominal fat in patients with anorexia nervosa. Diabetologie Metabolismus Endokrinologie Výživa. 2001;(supplement 3):p. 28.

Bartak V, Nedvidkova J, Vybiral S, et al. Adrenergic regulation of lipolysis in patients with anorexia nervosa during exercise. Physiological Research. 2003;52:p. 24P.

Nedvidkova J, Dostalova I, Bartak V, Papezova H, Pacak K. Increased subcutaneous abdominal tissue norepinephrine levels in patients with anorexia nervosa: an in vivo microdialysis study. Physiological Research. 2004;53:409–413. PubMed

Bartak V, Vybiral S, Papezova H, Dostalova I, Pacak K, Nedvidkova J. Basal and exercise-induced sympathetic nervous activity and lipolysis in adipose tissue of patients with anorexia nervosa. European Journal of Clinical Investigation. 2004;34(5):371–377. PubMed

Brambilla F. Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment. CNS Drugs. 2001;15(2):119–136. PubMed

Takimoto Y, Inui A, Kumano H, Kuboki T. Orexigenic/anorexigenic signals in Bulimia nervosa. Current Molecular Medicine. 2003;3(4):349–360. PubMed

Jimerson DC, Wolfe BE. Neuropeptides in eating disorders. CNS Spectrums. 2004;9(7):516–522. PubMed

Harrold JA. Hypothalamic control of energy balance. Current Drug Targets. 2004;5(3):207–219. PubMed

Torsello A, Brambilla F, Tamiazzo L, et al. Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. Journal of Endocrinological Investigation. 2007;30(11):962–976. PubMed

Nunn K, Frampton I, Lask B. Anorexia nervosa—a noradrenergic dysregulation hypothesis. Medical Hypotheses. 2012;78(5):580–584. PubMed

Corcos M, Atger F, Lévy-Soussan P, et al. Bulimia nervosa and autoimmunity. Psychiatry Research. 1999;87(1):77–82. PubMed

Fetissov SO, Hamze Sinno M, Coquerel Q, et al. Emerging role of autoantibodies against appetite-regulating neuropeptides in eating disorders. Nutrition. 2008;24(9):854–859. PubMed

Fetissov SO, Harro J, Jaanisk M, et al. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(41):14865–14870. PubMed PMC

Fetissov SO. In search of the missing link in the regulation of appetite and body weight. Nutrition. 2009;25(3):252–254. PubMed

Fetissov SO, Hamze Sinno M, Coëffier M, et al. Autoantibodies against appetite-regulating peptide hormones and neuropeptides: putative modulation by gut microflora. Nutrition. 2008;24(4):348–359. PubMed PMC

Terashi M, Asakawa A, Harada T, et al. Ghrelin reactive autoantibodies in restrictive anorexia nervosa. Nutrition. 2011;27(4):407–413. PubMed

Radermecker RP, Renard E, Scheen AJ. Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes/Metabolism Research and Reviews. 2009;25(6):491–501. PubMed

Franke B, Galloway TS, Wilkin TJ. Developments in the prediction of type 1 diabetes mellitus, with special reference to insulin autoantibodies. Diabetes/Metabolism Research and Reviews. 2005;21(5):395–415. PubMed

Prioletta A, Muscogiuri G, Sorice GP, et al. In anorexia nervosa, even a small increase in abdominal fat is responsible for the appearance of insulin resistance. Clinical Endocrinology. 2011;75(2):202–206. PubMed

Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. Journal of Clinical Endocrinology and Metabolism. 2001;86(10):4753–4758. PubMed

Zhu X, Cao Y, Voogd K, Steiner DF. On the processing of proghrelin to ghrelin. Journal of Biological Chemistry. 2006;281:38867–38870. PubMed

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. PubMed

Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132(3):387–396. PubMed

Müller TD, Tschöp MH, Jarick I, et al. Genetic variation of the ghrelin activator gene ghrelin O-acyltransferase (GOAT) is associated with anorexia nervosa. Journal of Psychiatric Research. 2011;45(5):706–711. PubMed

Kirchner H, Gutierrez JA, Solenberg PJ, et al. GOAT links dietary lipids with the endocrine control of energy balance. Nature Medicine. 2009;15:741–745. PubMed PMC

Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. Journal of Endocrinological Investigation. 2000;23(8):493–495. PubMed

Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in Ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123(4):1120–1128. PubMed

Nonogaki K. Ghrelin and feedback systems. Vitamins and Hormones. 2007;77:149–170. PubMed

Asakawa A, Inui A, Fujimiya M, et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut. 2005;54(1):18–24. PubMed PMC

Cassoni P, Papotti M, Ghè C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. Journal of Clinical Endocrinology and Metabolism. 2001;86(4):1738–1745. PubMed

Banks WA, Tschöp M, Robinson SM, Heiman ML. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. Journal of Pharmacology and Experimental Therapeutics. 2002;302(2):822–827. PubMed

Chen C-Y, Inui A, Asakawa A, et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology. 2005;129(1):8–25. PubMed

Inhoff T, Wiedenmann B, Klapp BF, Mönnikes H, Kobelt P. Is desacyl ghrelin a modulator of food intake? Peptides. 2009;30(5):991–994. PubMed

Sedláčková D, Dostálová I, Hainer V, et al. Simultaneous decrease of plasma obestatin and ghrelin levels after a high-carbohydrate breakfast in healthy women. Physiological Research. 2008;57(1):S29–S37. PubMed

Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004;145(6):2607–2612. PubMed

Hozumi H, Yamanouchi K, Nishihara M. Involvement of neuropeptide Y in hyperphagia in human growth hormone transgenic rats. Journal of Veterinary Medical Science. 2006;68(9):959–965. PubMed

Date Y, Shimbara T, Koda S, et al. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metabolism. 2006;4(4):323–331. PubMed

Ogiso K, Asakawa A, Amitani H, Inui A. Ghrelin and anorexia nervosa: a psychosomatic perspective. Nutrition. 2011;27(10):988–993. PubMed

Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone (GH) release in humans. Journal of Clinical Endocrinology and Metabolism. 2000;85(12):4908–4911. PubMed

Vestergaard ET, Dall R, Lange KHW, Kjaer M, Christiansen JS, Jorgensen JOL. The ghrelin response to exercise before and after growth hormone administration. Journal of Clinical Endocrinology and Metabolism. 2007;92(1):297–303. PubMed

Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism. 2002;87(1):240–244. PubMed

Cummings DE, Weigle DS, Scott Frayo R, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine. 2002;346(21):1623–1630. PubMed

Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817):194–198. PubMed

Van Der Lely AJ. Ghrelin and new metabolic frontiers. Hormone Research. 2009;71(1):129–133. PubMed

Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495–522. PubMed

Liu J, Lin H, Cheng P, Hu X, Lu H. Effects of ghrelin on the proliferation and differentiation of 3T3-L1 preadipocytes. Journal of Huazhong University of Science and Technology. 2009;29(2):227–230. PubMed

Rodríguez A, Gómez-Ambrosi J, Catalán V, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. International Journal of Obesity. 2009;33:541–552. PubMed

Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):3062–3065. PubMed

Thompson NM, Gill DAS, Davies R, et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directlyin vivo by a mechanism independent of GHS-R1a. Endocrinology. 2004;145(1):234–242. PubMed

Tebbe JJ, Tebbe CG, Mronga S, Ritter M, Schäfer MKH. Central neuropeptide Y receptors are involved in 3rd ventricular ghrelin induced alteration of colonic transit time in conscious fed rats. BMC Gastroenterology. 2005;5, article 5 PubMed PMC

Kos K, Harte AL, O’Hare PJ, Kumar S, McTernan PG. Ghrelin and the differential regulation of des-acyl (DSG) and oct-anoyl ghrelin (OTG) in human adipose tissue (AT) Clinical Endocrinology. 2009;70(3):383–389. PubMed

Misra M, Miller KK, Stewart V, et al. Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5082–5087. PubMed

Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. European Journal of Endocrinology. 2001;145(5):669–673. PubMed

Otto B, Tschöp M, Cuntz U. Letter to the Editor: similar fasting ghrelin levels in binge eating/purging anorexia nervosa and restrictive anorexia nervosa. Psychoneuroendocrinology. 2004;29(5):692–693. PubMed

Troisi A, Di Lorenzo G, Lega I, et al. Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones. Neuroendocrinology. 2005;81(4):259–266. PubMed

Yin X, Li Y, Xu G, An W, Zhang W. Ghrelin fluctuation, what determines its production? Acta Biochimica et Biophysica Sinica. 2009;41(3):188–197. PubMed

Karczewska-Kupczewska M, Straczkowski M, Adamska A, et al. Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa. European Journal of Endocrinology. 2010;162(2):235–239. PubMed

Janas-Kozik M, Krupka-Matuszczyk I, Malinowska-Kolodziej I, Lewin-Kowalik J. Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa. Regulatory Peptides. 2007;140(1-2):43–46. PubMed

Nedvidkova J, Krykorkova I, Bartak V, et al. Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2003;88(4):1678–1682. PubMed

Hotta M, Ohwada R, Katakami H, Shibasaki T, Hizuka N, Takano K. Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2004;89(11):5707–5712. PubMed

Germain N, Galusca B, Grouselle D, et al. Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2010;95(6):3057–3062. PubMed

Scacchi M, Pincelli AI, Cavagnini F. Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa. Frontiers in Neuroendocrinology. 2003;24(3):200–224. PubMed

Støving RK, Andersen M, Flyvbjerg A, et al. Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa. Clinical Endocrinology. 2002;56(3):391–396. PubMed

Gianotti L, Fassino S, Daga GA, et al. Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to ghrh in anorexia nervosa. Clinical Endocrinology. 2000;52(6):713–720. PubMed

Broglio F, Gianotti L, Destefanis S, et al. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clinical Endocrinology. 2004;60(5):592–599. PubMed

Misra M, Klibanski A. The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology. 2011;93(2):65–73. PubMed PMC

Fazeli PK, Lawson EA, Prabhakaran R, et al. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2010;95(11):4889–4897. PubMed PMC

Hasan TF, Hasan H. Anorexia nervosa: a unified neurological perspective. International Journal of Medical Sciences. 2011;8(8):679–703. PubMed PMC

Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2010;95(1):369–374. PubMed PMC

Monteleone P, Carratù R, Cartenì M, et al. Intestinal permeability is decreased in anorexia nervosa. Molecular Psychiatry. 2004;9(1):76–80. PubMed

Naisberg Y, Modai I, Weizman A. Metabolic bioenergy homeostatic disruption: a cause of anorexia nervosa. Medical Hypotheses. 2001;56(4):454–461. PubMed

Hornig M, Lipkin WI. Immune-mediated animal models of Tourette syndrome. Neuroscience & Biobehavioral Reviews. 2013;37:1120–1138. PubMed PMC

Germain N, Galusca B, Grouselle D, et al. Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology. 2009;34(3):413–419. PubMed

Nakai Y, Hosoda H, Nin K, et al. Plasma levels of active form of ghrelin during oral glucose tolerance test in patients with anorexia nervosa. European Journal of Endocrinology. 2003;149(1):R1–R3. PubMed

Harada T, Nakahara T, Yasuhara D, et al. Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biological Psychiatry. 2008;63(2):245–247. PubMed

Tanaka M, Naruo T, Muranaga T, et al. Increased fasting plasma ghrelin levels in patients with bulimia nervosa. European Journal of Endocrinology. 2002;146(6):R1–R3. PubMed

Tanaka M, Naruo T, Nagai N, et al. Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders. Journal of Psychiatric Research. 2003;37(1):17–22. PubMed

Monteleone P, Martiadis V, Rigamonti AE, et al. Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. Biological Psychiatry. 2005;57(8):926–931. PubMed

Kojima S, Nakahara T, Nagai N, et al. Altered ghrelin and peptide YY responses to meals in bulimia nervosa. Clinical Endocrinology. 2005;62(1):74–78. PubMed

Monteleone P, Martiadis V, Fabrazzo M, Serritella C, Maj M. Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. Psychological Medicine. 2003;33(8):1387–1394. PubMed

Fassino S, Abbate Daga G, Mondelli V, et al. Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa. Psychoneuroendocrinology. 2005;30(6):534–540. PubMed

Agnew AJ, Robinson E, McVicar CM, et al. The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. British Journal of Pharmacology. 2012;166(1):327–338. PubMed PMC

Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology. 2007;148(1):21–26. PubMed

Zamrazilová H, Hainer V, Sedláčková D, et al. Plasma obestatin levels in normal weight, obese and anorectic women. Physiological Research. 2008;57(1):S49–S55. PubMed

Haider DG, Schindler K, Prager G, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. Journal of Clinical Endocrinology and Metabolism. 2007;92(3):1168–1171. PubMed

Gourcerol G, St-Pierre DH, Taché Y. Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regulatory Peptides. 2007;141(1–3):1–7. PubMed

Van Dijck A, Van Dam D, Vergote V, et al. Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regulatory Peptides. 2009;156(1–3):77–82. PubMed

Qader SS, Håkanson R, Rehfeld JF, Lundquist I, Salehi A. Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: a study on isolated islets from mouse and rat pancreas. Regulatory Peptides. 2008;146(1–3):230–237. PubMed

Samson WK, White MM, Price C, Ferguson AV. Obestatin acts in brain to inhibit thirst. American Journal of Physiology. Regulatory Integrative and Comparative Physiology. 2007;292(1):R637–R643. PubMed

Camiña JP, Campos JF, Caminos JE, Dieguez C, Casanueva FF. Obestatin-mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. Journal of Cellular Physiology. 2007;211(1):1–9. PubMed

Kapica M, Zabielska M, Puzio I, et al. Obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats—preliminary results. Journal of Physiology and Pharmacology. 2007;58(3):123–130. PubMed

Ren A-J, Guo Z-F, Wang Y-K, et al. Inhibitory effect of obestatin on glucose-induced insulin secretion in rats. Biochemical and Biophysical Research Communications. 2008;369(3):969–972. PubMed

Pan W, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides. 2006;27(4):911–916. PubMed

Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides. 2008;29(10):1740–1748. PubMed

Egido EM, Hernández R, Marco J, Silvestre RA. Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regulatory Peptides. 2009;152(1–3):61–66. PubMed

Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochemical and Biophysical Research Communications. 2006;351(1):21–25. PubMed

Zhang JV, Jahr H, Luo C-W, et al. Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Molecular Endocrinology. 2008;22(6):1464–1475. PubMed PMC

Egerod KL, Holst B, Petersen PS, et al. GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Molecular Endocrinology. 2007;21(7):1685–1698. PubMed

Catalán V, Gómez-Ambrosi J, Rotellar F, et al. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus. Clinical Endocrinology. 2007;66(4):598–601. PubMed

Dong X-Y, He J-M, Tang S-Q, Li H-Y, Jiang Q-Y, Zou X-T. Is GPR39 the natural receptor of obestatin? Peptides. 2009;30(2):431–438. PubMed

Granata R, Settanni F, Gallo D, et al. Obestatin promotes survival of pancreatic β-cells and human islets and induces expression of genes involved in the regulation of β-cell mass and function. Diabetes. 2008;57(4):967–979. PubMed

Fujimiya M, Ataka K, Asakawa A, Chen C-Y, Kato I, Inui A. Regulation of gastroduodenal motility: acyl ghrelin, des-acyl ghrelin and obestatin and hypothalamic peptides. Digestion. 2012;85(2):90–94. PubMed

Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. Journal of Clinical Endocrinology and Metabolism. 2008;93(11):4418–4421. PubMed

Nakahara T, Harada T, Yasuhara D, et al. Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biological Psychiatry. 2008;64(3):252–255. PubMed

Uehara M, Yasuhara D, Nakahara T, et al. Increase in energy intake leads to a decrease in obestatin in restricting-type of anorexia nervosa. Experimental and Clinical Endocrinology and Diabetes. 2011;119(9):536–539. PubMed

Neary NM, Small CJ, Bloom SR. Gut and mind. Gut. 2003;52(7):918–921. PubMed PMC

Sahu A, Kalra SP. Neuropeptidergic regulation of feeding behavior: neuropeptide Y. Trends in Endocrinology and Metabolism. 1993;4(7):217–224. PubMed

Wynne K, Stanley S, McGowan B, Bloom SR. Appetite control. Journal of Endocrinology. 2005;184(2):291–318. PubMed

Turtzo LC, Lane MD. NPY and neuron-adipocyte interactions in the regulation of metabolism. EXS. 2006;(95):133–141. PubMed

Turtzo LC, Marx R, Daniel Lane M. Cross-talk between sympathetic neurons and adipocytes in coculture. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(22):12385–12390. PubMed PMC

Nogueiras R, Williams LM, Dieguez C. Ghrelin: new molecular pathways modulating appetite and adiposity. Obesity Facts. 2010;3(5):285–292. PubMed PMC

Coiro V, Volpi R, Cataldo S, et al. Somatostatin reduces neuropeptide Y rise induced by physical exercise. Hormone and Metabolic Research. 2011;43(5):361–363. PubMed

Coiro V, Casti A, Volta E, et al. Effect of physical training on reduction of circulating neuropeptide Y levels in elderly humans. Journal of Endocrinological Investigation. 2010;33(2):132–133. PubMed

Antonijevic IA, Murck H, Bohlhalter S, Frieboes R-M, Holsboer F, Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology. 2000;39(8):1474–1481. PubMed

Watanobe H, Tamura T. Stimulation by neuropeptide Y of growth hormone secretion in prolactinoma in vivo. Neuropeptides. 1996;30(5):429–432. PubMed

Watanobe H, Tamura T. Stimulatory and inhibitory effects of neuropeptide Y on growth hormone secretion in acromegaly in vivo. Neuropeptides. 1997;31(1):29–34. PubMed

Pihlajamäki J, Karhapää P, Vauhkonen I, et al. The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism. Metabolism. 2003;52(5):643–646. PubMed

Billington CJ, Briggs JE, Grace M, Levine AS. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. American Journal of Physiology. Regulatory Integrative and Comparative Physiology. 1991;260(2):R321–R327. PubMed

Kos K, Harte AL, James S, et al. Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. American Journal of Physiology. Endocrinology and Metabolism. 2007;293(5):E1335–E1340. PubMed

Yang K, Guan H, Arany E, Hill DJ, Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB Journal. 2008;22(7):2452–2464. PubMed

Kos K, Baker AR, Jernas M, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes, Obesity and Metabolism. 2009;11(4):285–292. PubMed

Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetňanský R, Zukowska Z. Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Annals of the New York Academy of Sciences. 2008;1148:232–237. PubMed PMC

Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Current Topics in Medicinal Chemistry. 2007;7(17):1645–1659. PubMed

Gruninger TR, LeBoeuf B, Liu Y, Garcia LR. Molecular signaling involved in regulating feeding and other motivated behaviors. Molecular Neurobiology. 2007;35(1):1–19. PubMed

Hökfelt T, Stanic D, Sanford SD, et al. NPY and its involvement in axon guidance, neurogenesis, and feeding. Nutrition. 2008;24(9):860–868. PubMed

Hargrave SL, Kinzig KP. Repeated gastric distension alters food intake and neuroendocrine profiles in rats. Physiology and Behavior. 2012;105(4):975–981. PubMed PMC

Baranowska B, Wasilewska-Dziubińska E, Radzikowska M, Płonowski A, Roguski K. Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa. Metabolism. 1997;46(12):1384–1389. PubMed

Nedvídková J, Papezová H, Haluzík M, Schreiber V. Interaction between serum leptin levels and hypothalamo-hypophyseal-thyroid axis in patients with anorexia nervosa. Endocrine Research. 2000;26(2):219–230. PubMed

Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, Roguski K, Chmielowska M. Plasma leptin, neuropeptide Y (NPY) and galanin concentrations in bulimia nervosa and in anorexia nervosa. Neuroendocrinology Letters. 2001;22(5):356–358. PubMed

Oświecimska J, Ziora K, Geisler G, Broll-Waśka K. Prospective evaluation of leptin and neuropeptide Y (NPY) serum levels in girls with anorexia nervosa. Neuroendocrinology Letters. 2005;26(4):301–304. PubMed

Sederholm F, Ammar AA, Södersten P. Intake inhibition by NPY: role of appetitive ingestive behavior and aversion. Physiology and Behavior. 2002;75(4):567–575. PubMed

Ammar AA, Nergårdh R, Fredholm BB, Brodin U, Södersten P. Intake inhibition by NPY and CCK-8: a challenge of the notion of NPY as an “Orexigen”. Behavioural Brain Research. 2005;161(1):82–87. PubMed

Nergårdh R, Ammar A, Brodin U, Bergström J, Scheurink A, Södersten P. Neuropeptide Y facilitates activity-based-anorexia. Psychoneuroendocrinology. 2007;32(5):493–502. PubMed

Pedersen-Bjergaard U, Høst U, Kelbæk H, et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scandinavian Journal of Clinical and Laboratory Investigation. 1996;56(6):497–503. PubMed

Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. Journal of Pharmacology and Experimental Therapeutics. 2003;306(3):948–953. PubMed

Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature. 2002;418(6898):650–654. PubMed

Brunetti L, Orlando G, Ferrante C, Chiavaroli A, Vacca M. Peptide YY (3–36) inhibits dopamine and norepinephrine release in the hypothalamus. European Journal of Pharmacology. 2005;519(1-2):48–51. PubMed

Corp ES, McQuade J, Krasnicki S, Conze DB. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides. 2001;22(3):493–499. PubMed

Druce MR, Small CJ, Bloom SR. Minireview: gut peptides regulating satiety. Endocrinology. 2004;145(6):2660–2665. PubMed

Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005;129(5):1430–1436. PubMed

Harding RK, McDonald TJ. Identification and characterization of the emetic effects of peptide YY. Peptides. 1989;10(1):21–24. PubMed

Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36 . New England Journal of Medicine. 2003;349(10):941–948. PubMed

Tong J, D'Alessio D. Eating disorders and gastrointestinal peptides. Current Opinion in Endocrinology, Diabetes and Obesity. 2011;18:42–49. PubMed

Ueda S-Y, Yoshikawa T, Katsura Y, Usui T, Fujimoto S. Comparable effects of moderate intensity exercise on changes in anorectic gut hormone levels and energy intake to high intensity exercise. Journal of Endocrinology. 2009;203(3):357–364. PubMed

Nguyen AD, Herzog H, Sainsbury A. Neuropeptide Y and peptide YY: important regulators of energy metabolism. Current Opinion in Endocrinology, Diabetes and Obesity. 2011;18(1):56–60. PubMed

Labelle M, Boulanger Y, Fournier A, St.-Pierre S, Savard R. Tissue-specific regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats. Peptides. 1997;18(6):801–808. PubMed

Monteleone P, Castaldo E, Maj M. Neuroendocrine dysregulation of food intake in eating disorders. Regulatory Peptides. 2008;149(1–3):39–50. PubMed

Stock S, Leichner P, Wong ACK, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. Journal of Clinical Endocrinology and Metabolism. 2005;90(4):2161–2168. PubMed

Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):1027–1033. PubMed

Nakahara T, Kojima S, Tanaka M, et al. Incomplete restoration of the secretion of ghrelin and PYY compared to insulin after food ingestion following weight gain in anorexia nervosa. Journal of Psychiatric Research. 2007;41(10):814–820. PubMed

Lawson EA, Eddy KT, Donoho D, et al. Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index. European Journal of Endocrinology. 2011;164(2):253–261. PubMed PMC

Germain N, Galusca B, Le Roux CW, et al. Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. American Journal of Clinical Nutrition. 2007;85(4):967–971. PubMed

Kaye WH, Berrettini W, Gwirtsman H, George DT. Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Archives of General Psychiatry. 1990;47(6):548–556. PubMed

Gendall KA, Kaye WH, Altemus M, McConaha CW, La Via MC. Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biological Psychiatry. 1999;46(2):292–299. PubMed

Devlin MJ, Kissileff HR, Zimmerli EJ, et al. Gastric emptying and symptoms of bulimia nervosa: effect of a prokinetic agent. Physiology and Behavior. 2012;106(2):238–242. PubMed PMC

Geracioti TD, Jr., Liddle RA. Impaired cholecystokinin secretion in bulimia nervosa. New England Journal of Medicine. 1988;319(11):683–688. PubMed

Lin HC, Chey WY, Zhao X-T. Release of distal gut peptide YY (PYY) by fat in proximal gut depends on CCK. Peptides. 2000;21(10):1561–1563. PubMed

Dockray GJ. Cholecystokinin and gut-brain signalling. Regulatory Peptides. 2009;155(1–3):6–10. PubMed

Chandra R, Liddle RA. Cholecystokinin. Current Opinion in Endocrinology, Diabetes and Obesity. 2007;14(1):63–67. PubMed

Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. Journal of Comparative and Physiological Psychology. 1973;84(3):488–495. PubMed

Degen L, Matzinger D, Drewe J, Beglinger C. The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides. 2001;22(8):1265–1269. PubMed

Woods SC. Gastrointestinal Satiety Signals. I. An overview of gastrointestinal signals that influence food intake. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2004;286(1):G7–G13. PubMed

Hisadome K, Reimann F, Gribble FM, Trapp S. CCK stimulation of GLP-1 neurons involves α1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes. 2011;60(11):2701–2709. PubMed PMC

Dourish CT, Rycroft W, Iversen SD. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors. Science. 1989;245(4925):1509–1511. PubMed

Chen H, Kent S, Morris MJ. Is the CCK2 receptor essential for normal regulation of body weight and adiposity? European Journal of Neuroscience. 2006;24(5):1427–1433. PubMed

Clerc P, Constans MGC, Lulka H, et al. Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. Endocrinology. 2007;148(3):1039–1049. PubMed

Philipp E, Pirke K-M, Kellner MB, Krieg J-C. Disturbed cholecystokinin secretion in patients with eating disorders. Life Sciences. 1991;48(25):2443–2450. PubMed

Tamai H, Takemura J, Kobayashi N, Matsubayashi S, Matsukura S, Nakagawa T. Changes in plasma cholecystokinin concentrations after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism. 1993;42(5):581–584. PubMed

Harty RF, Pearson PH, Solomon TE, McGuigan JE. Cholecystokinin, vasoactive intestinal peptide and peptide histidine methionine responses to feeding in anorexia nervosa. Regulatory Peptides. 1991;36(1):141–150. PubMed

Brambilla F, Brunetta M, Peirone A, et al. T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. Psychiatry Research. 1995;59(1-2):43–50. PubMed

Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes, Obesity and Metabolism. 2000;2(2):99–103. PubMed

Cuntz U, Enck P, Frühauf E, et al. Cholecystokinin revisited: CCK and the hunger trap in anorexia nervosa. PLoS ONE. 2013;8e54457 PubMed PMC

Lydiard RB, Brewerton TD, Fossey MD, et al. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. American Journal of Psychiatry. 1993;150(7):1099–1101. PubMed

Devlin MJ, Walsh BT, Guss JL, Kissileff HR, Liddle RA, Petkova E. Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. American Journal of Clinical Nutrition. 1997;65(1):114–120. PubMed

Bailer UF, Kaye WH. A review of neuropeptide and neuroendocrine dysregulation in anorexia and bulimia nervosa. Current Drug Targets. CNS and Neurological Disorders. 2003;2(1):53–59. PubMed

Hannon-Engel S. Regulating satiety in bulimia nervosa: the role of cholecystokinin. Perspectives in Psychiatric Care. 2012;48(1):34–40. PubMed PMC

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432. PubMed

Bado A, Levasseur S, Attoub S, et al. The stomach is a source of leptin. Nature. 1998;394(6695):790–793. PubMed

Jin L, Burguera BG, Couce ME, et al. Leptin and leptin receptor expression in normal and neoplastic human pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation. Journal of Clinical Endocrinology and Metabolism. 1999;84(8):2903–2911. PubMed

Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. International Journal of Obesity. 2003;27(8):875–888. PubMed

Anubhuti V, Arora S. Leptin and its metabolic interactions—an update. Diabetes, Obesity and Metabolism. 2008;10(11):973–993. PubMed

Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochemical and Biophysical Research Communications. 2001;283(4):982–988. PubMed

Stein K, Vasquez-Garibay E, Kratzsch J, Romero-Velarde E, Jahreis G. Influence of nutritional recovery on the leptin axis in severely malnourished children. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):1021–1026. PubMed

Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543–546. PubMed

Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. Journal of Clinical Investigation. 1997;100(2):270–278. PubMed PMC

Tang-Christensen M, Havel PJ, Jacobs RR, Larsen PJ, Cameron JL. Central administration of leptin inhibits food intake and activates the sympathetic nervous system in rhesus macaques. Journal of Clinical Endocrinology and Metabolism. 1999;84(2):711–717. PubMed

Lissett CA, Clayton PE, Shalet SM. The acute leptin response to GH. Journal of Clinical Endocrinology and Metabolism. 2001;86(9):4412–4415. PubMed

Kalra SP, Ueno N, Kalra PS. Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. Journal of Nutrition. 2005;135(5):1331–1335. PubMed

Carro E, Seoane LM, Señaris R, Considine RV, Casanueva FF, Dieguez C. Interaction between leptin and neuropeptide Y on in vivo growth hormone secretion. Neuroendocrinology. 1998;68(3):187–191. PubMed

Dieguez C, Carro E, Seoane LM, et al. Regulation of somatotroph cell function by the adipose tissue. International Journal of Obesity. 2000;24(2):S100–S103. PubMed

Misra M, Miller KK, Kuo K, et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. American Journal of Physiology. Endocrinology and Metabolism. 2005;289(3):E373–E381. PubMed

Zhao Z, Sakata I, Okubo Y, Koike K, Kangawa K, Sakai T. Gastric leptin, but not estrogen and somatostatin, contributes to the elevation of ghrelin mRNA expression level in fasted rats. Journal of Endocrinology. 2008;196(3):529–538. PubMed

Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S. Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach. Regulatory Peptides. 2004;119(1-2):77–81. PubMed

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707–709. PubMed

Frühbeck G, Aguado M, Martinez JA. In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine/paracrine role of leptin. Biochemical and Biophysical Research Communications. 1997;240(3):590–594. PubMed

Frühbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiology. Clinical Physiology. 1998;18(5):399–419. PubMed

Bai Y, Zhang S, Kim K-S, Lee J-K, Kim K-H. Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. Journal of Biological Chemistry. 1996;271(24):13939–13942. PubMed

Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382(6588):250–252. PubMed

Holtkamp K, Herpertz-Dahlmann B, Mika C, et al. Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism. 2003;88(11):5169–5174. PubMed

Dostalova I, Kopsky V, Duskova J, Papezová H, Pacak K, Nedvidkova J. Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. Regulatory Peptides. 2005;128:63–68. PubMed

Zepf FD, Sungurtekin I, Glass F, et al. Differences in zinc status and the leptin axis in anorexic and recovered adolescents and young adults: a pilot study. Food and Nutrition Research. 2012;56(1):1–8. PubMed PMC

Housova J, Anderlova K, Krizová J, et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. Journal of Clinical Endocrinology and Metabolism. 2005;90(3):1366–1370. PubMed

Monteleone P, Bortolotti F, Fabrazzo M, La Rocca A, Fuschino A, Maj M. Plasma leptin response to acute fasting and refeeding in untreated women with bulimia nervosa. Journal of Clinical Endocrinology and Metabolism. 2000;85(7):2499–2503. PubMed

Brewerton TD, Lesem MD, Kennedy A, Garvey WT. Reduced plasma leptin concentrations in bulimia nervosa. Psychoneuroendocrinology. 2000;25(7):649–658. PubMed

Zipfel S, Specht T, Blum WF, et al. Leptin-a parameter for body fat measurement in patients with eating disorders. European Eating Disorders Review. 1998;6:38–47.

Jimerson DC, Mantzoros C, Wolfe BE, Metzger ED. Decreased serum leptin in bulimia nervosa. Journal of Clinical Endocrinology and Metabolism. 2000;85(12):4511–4514. PubMed

Monteleone P, Martiadis V, Colurcio B, Maj M. Leptin secretion is related to chronicity and severity of the illness in bulimia nervosa. Psychosomatic Medicine. 2002;64(6):874–879. PubMed

Vestergaard ET, Hansen TK, Nielsen S, Moller N, Christiansen JS, Jorgensen JOL. Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis. European Journal of Endocrinology. 2005;153(4):545–549. PubMed

Inui A. Eating behavior in anorexia nervosa—an excess of both orexigenic and anorexigenic signalling? Molecular Psychiatry. 2001;6(6):620–624. PubMed

Miller KK. Endocrine dysregulation in anorexia nervosa update. Journal of Clinical Endocrinology and Metabolism. 2011;96(10):2939–2949. PubMed PMC

Acres MJ, Heath JJ, Morris JA. Anorexia nervosa, autoimmunity and the hygiene hypothesis. Medical Hypotheses. 2012;78(6):772–775. PubMed

Takii M, Uchigata Y, Kishimoto J, et al. The relationship between the age of onset of type 1 diabetes and the subsequent development of a severe eating disorder by female patients. Pediatric Diabetes. 2011;12(4):396–401. PubMed

Prasad-Reddy L. Disordered eating in type 1 diabetes: insulin omission and diabulimia. U.S. Pharmacist. 2012;37:1–8.

Geiger BM, Behr GG, Frank LE, et al. Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB Journal. 2008;22(8):2740–2746. PubMed PMC

Van den Eynde F, Treasure J. Neuroimaging in eating disorders and obesity: implications for research. Child and Adolescent Psychiatric Clinics of North America. 2009;18(1):95–115. PubMed

Batterham RL, Ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007;450(7166):106–109. PubMed

Malik S, McGlone F, Bedrossian D, Dagher A. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metabolism. 2008;7(5):400–409. PubMed

Monteleone P, Serritella C, Martiadis V, Maj M. Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. Biological Psychiatry. 2008;64(11):1005–1008. PubMed

Kaye WH, Fudge JL, Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. Nature Reviews Neuroscience. 2009;10(8):573–584. PubMed

Fladung A-K, Grön G, Grammer K, et al. A neural signature of anorexia nervosa in the ventral striatal reward system. American Journal of Psychiatry. 2010;167(2):206–212. PubMed

Monteleone P. New frontiers in endocrinology of eating disorders. Current Topics in Behavioral Neurosciences. 2011;6:189–208. PubMed

Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. Psychoneuroendocrinology. 2013;38:312–330. PubMed

Holsen LM, Lawson EA, Blum J, et al. Food motivation circuitry hypoactivation related to hedonic and nonhedonic aspects of hunger and satiety in women with active anorexia nervosa and weight-restored women with anorexia nervosa. Journal of Psychiatry & Neuroscience . 2012;37:322–332. PubMed PMC

Capasso A, Petrella C, Milano W. Recent clinical aspects of eating disorders. Reviews on Recent Clinical Trials. 2009;4(1):63–69. PubMed

Hebebrand J, Albayrak Ö. Leptin treatment of patients with anorexia nervosa? The urgent need for initiation of clinical studies. European Child and Adolescent Psychiatry. 2012;21(2):63–66. PubMed

Bou Khalil R, de Muylder O, Hebborn FL. Treatment of anorexia nervosa with TNF-α down-regulating agents. Eating and Weight Disorders. 2011;16e300 PubMed

Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry. 2008;165(10):1281–1288. PubMed

Banks WA. Blood-brain barrier as a regulatory interface. Forum of Nutrition. 2010;63:102–110. PubMed

Hofbauer KG, Lecourt A-C, Peter J-C. Antibodies as pharmacologic tools for studies on the regulation of energy balance. Nutrition. 2008;24(9):791–797. PubMed

Verhagen LAW, Egecioglu E, Luijendijk MCM, Hillebrand JJG, Adan RAH, Dickson SL. Acute and chronic suppression of the central ghrelin signaling system reveals a role in food anticipatory activity. European Neuropsychopharmacology. 2011;21(5):384–392. PubMed

Cardona Cano S, Merkestein M, Skibicka KP, Dickson SL, Adan RAH. Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy. CNS Drugs. 2012;26(4):281–296. PubMed

Herpertz-Dahlmann B, Holtkamp K, Konrad K. Eating disorders: anorexia and bulimia nervosa. Handbook of Clinical Neurology. 2012;106:447–462. PubMed

Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. International Journal of Neuropsychopharmacology. 2012;15(2):209–222. PubMed

Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. Journal of Clinical Psychiatry. 2012;73:e757–e766. PubMed

Garcia FD, Coquerel Q, do Rego J-C, et al. Anti-neuropeptide Y plasma immunoglobulins in relation to mood and appetite in depressive disorder. Psychoneuroendocrinology. 2012;73(9):1457–1467. PubMed

Fetissov SO, Déchelotte P. The new link between gut-brain axis and neuropsychiatric disorders. Current Opinion in Clinical Nutrition and Metabolic Care. 2011;14(5):477–482. PubMed

Current Aspects of the Role of Autoantibodies Directed Against Appetite-Regulating Hormones and the Gut Microbiome in Eating Disorders

Acipimox Administration With Exercise Induces a Co-feedback Action of the GH, PP, and PYY on Ghrelin Associated With a Reduction of Peripheral Lipolysis in Bulimic and Healthy-Weight Czech Women: A Randomized Study